PRRSV (Porcine Reproductive and respiratory syndrome virus) is one of the most loss-causing agents in the global swine production. Partly due to reproductive losses plus birth of weak and viremic piglets from females viremic between day 70 of gestation and farrowing, partly due to the immunosuppressive action and respiratory disease in the infected naïve animal at any age. The virus is highly mutating and easily recombining between different strains into entirely new strains of potential high virulence. To control PRRSV on endemic farms internal biosecurity is key, which very often is an unfulfilled challenge. Finally, the single optimal PRRSV vaccine is not yet developed; MLV (modified live virus) PRRS vaccines have strong protection for “own” strain but poor cross-protection. INV (inactivated virus) PRRS vaccines have poor protection, when applied in naïve animals. However, Progressis produces a clinical and colostral protection when applied on previously naturally infected or MLV vaccinated animals. The optimal and safest PRRSV vaccination schedule is the Progressis Prime-Boost Concept, keeping breeding stock and new born PRRSV negative, with the potential of producing PRRSV negative piglets out of nurseries (app. 10 woa) depending on quality of biosecurity.
Why choose Progressis?
Safety (no live virus on farm)
Efficacy (better stabilization of the farm after a PRRSv outbreak)
Stable reproductive performances
The Science behind
Measuring How Recombination Re-shapes the Evolutionary History of PRRSV-2: A Genome-Based Phylodynamic Analysis of the Emergence of a Novel PRRSV-2 Variant
Nakarin Pamornchainavakul, Mariana Kikuti, Igor A. D. Paploski, Dennis N. Makau, Albert Rovira, Cesar A. Corzo and Kimberly VanderWaal
The use of a whole inactivated PRRS virus vaccine administered in sows and impact on maternally derived immunity and timing of PRRS virus infection in piglets
From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.
Respiporc Flu 3 and Respiporc Flu Pan H1N1, the registered range of Influenza vaccines, which delivers the broadest protection against Swine Influenza A Virus (swIAV).
The most efficacious vaccine to protect against reproductive failures & Erysipelas caused by PPV & Ery with exclusive, proven efficacy and maximum safety in its application.
You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
Warning message
These pages are not intended for users based in France.
Further, product information presented on these pages may be used by authorized professionals in the veterinary field only and/or may not be available in certain countries and are always subject to local regulatory requirements.
These pages are general information pages. No guarantee is given as to the completeness of the information contained or its compliance with national regulatory requirements. Users should consult the local site of their countries to obtain information that complies with applicable national regulations.